The protagonist of contemporary and emerging nanotechnology-based theranostics and therapeutic approaches in reshaping intensive care unit

References

1. 1.↵
   1. Wong HR

   . Intensive care medicine in 2050: precision medicine. Intensive Care Med 2017; 43: 1507-1509.

   OpenUrl
2. 2.↵
   1. Martin-Loeches I,
   2. Perner A

   . Focus on infection and sepsis in intensive care patients. Intensive Care Med 2016; 42: 491-493.

   OpenUrl
3. 3.↵
   1. Zilahi G,
   2. Artigas A,
   3. Martin-Loeches I

   . What’s new in multidrug-resistant pathogens in the ICU? Ann Intensive Care 2016; 6: 96.

   OpenUrlPubMed
4. 4.↵
   1. Perner A,
   2. Rhodes A,
   3. Venkatesh B,
   4. Angus DC,
   5. Martin-Loeches I,
   6. Preiser JC, et al.

   Sepsis: frontiers in supportive care, organisation and research. Intensive Care Med 2017; 43: 496-508.

   OpenUrl
5. 5.↵
   1. Martin-Loeches I,
   2. Deja M,
   3. Koulenti D,
   4. Dimopoulos G,
   5. Marsh B,
   6. Torres A, et al.

   Potentially resistant microorganisms in intubated patients with hospital-acquired pneumonia: the interaction of ecology, shock and risk factors. Intensive Care Med 2013; 39: 672-681.

   OpenUrlCrossRefPubMed
6. 6.↵
   1. Nwankire CE,
   2. Venkatanarayanan A,
   3. Glennon T,
   4. Keyes TE,
   5. Forster RJ,
   6. Ducrée J

   . Label-free impedance detection of cancer cells from whole blood on an integrated centrifugal microfluidic platform. Biosens Bioelectron 2015; 68: 382-389.

   OpenUrl
7. 7.↵
   1. Singh M,
   2. Tong Y,
   3. Webster K,
   4. Cesewski E,
   5. Haring AP,
   6. Laheri S, et al.

   3D printed conformal microfluidics for isolation and profiling of biomarkers from whole organs. Lab Chip 2017; 17: 2561-2571.

   OpenUrl
8. 8.↵
   1. Beitler JR,
   2. Goligher EC,
   3. Schmidt M,
   4. Spieth PM,
   5. Zanella A,
   6. Martin-Loeches I, et al.

   Personalized medicine for ARDS: the 2035 research agenda. Intensive Care Med 2016; 42: 756-767.

   OpenUrl
9. 9.↵
   1. Sakr Y,
   2. Lobo SM,
   3. Moreno RP,
   4. Gerlach H,
   5. Ranieri VM,
   6. Michalopoulos A, et al.

   Patterns and early evolution of organ failure in the intensive care unit and their relation to outcome. Crit Care 2012; 16: R222.

   OpenUrlCrossRefPubMed
10. 10.↵
    1. Bohmer N,
    2. Demarmels N,
    3. Tsolaki E,
    4. Gerken L,
    5. Keevend K,
    6. Bertazzo S, et al.

    Removal of cells from body fluids by magnetic separation in batch and continuous mode: influence of bead size, concentration, and contact time. ACS Appl Mater Interfaces 2017; 9: 29571-29579.

    OpenUrl
11. 11.↵
    1. Basit H,
    2. Maher S,
    3. Forster RJ,
    4. Keyes TE

    . Electrochemically triggered release of reagent to the proximal leaflet of a microcavity supported lipid bilayer. Langmuir 2017; 33: 6691-6700.

    OpenUrl
12. 12.↵
    1. Gobbo OL,
    2. Sjaastad K,
    3. Radomski MW,
    4. Volkov Y,
    5. Prina-Mello A

    . Magnetic nanoparticles in cancer theranostics. Theranostics 2015; 5: 1249-1263.

    OpenUrl
13. 13.↵
    1. Haque M,
    2. Sartelli M,
    3. McKimm J,
    4. Abu Bakar M

    . Health care-associated infections - an overview. Infect Drug Resist 2018; 11: 2321-2333.

    OpenUrlCrossRefPubMed
14. 14.↵
    1. Revelas A

    . Healthcare - associated infections: a public health problem. Niger Med J 2012; 53: 59-64.

    OpenUrlCrossRefPubMed
15. 15.↵
    1. Angus DC,
    2. van der Poll T

    . Severe sepsis and septic shock. N Engl J Med 2013; 369: 840-851.

    OpenUrlCrossRefPubMedWeb of Science
16. 16.↵
    1. Rittirsch D,
    2. Hoesel LM,
    3. Ward PA

    . The disconnect between animal models of sepsis and human sepsis. J Leukoc Biol 2007; 81: 137-143.

    OpenUrlCrossRefPubMedWeb of Science
17. 17.↵
    1. Kelly KL,
    2. Coronado E,
    3. Zhao LL,
    4. Schatz GC

    . The optical properties of metal nanoparticles: the influence of size, shape, and dielectric environment. ACS Publications 2003: 668-677.
18. 18.↵
    1. Atiyeh BS,
    2. Costagliola M,
    3. Hayek SN,
    4. Dibo SA

    . Effect of silver on burn wound infection control and healing: review of the literature. Burns 2007; 33: 139-148.

    OpenUrlCrossRefPubMedWeb of Science
19. 19.↵
    1. Rai M,
    2. Yadav A,
    3. Gade A

    . Silver nanoparticles as a new generation of antimicrobials. Biotechnol Adv 2009; 27: 76-83.

    OpenUrlCrossRefPubMedWeb of Science
20. 20.↵
    1. Wong KK,
    2. Liu X

    . Silver nanoparticles - the real “silver bullet” in clinical medicine? MedChemComm 2010; 1: 125-131.

    OpenUrl
21. 21.↵
    1. Munger MA,
    2. Radwanski P,
    3. Hadlock GC,
    4. Stoddard G,
    5. Shaaban A,
    6. Falconer J, et al.

    In vivo human time-exposure study of orally dosed commercial silver nanoparticles. Nanomedicine 2014; 10: 1-9.

    OpenUrlCrossRefPubMed
22. 22.↵
    1. Loher S,
    2. Schneider OD,
    3. Maienfisch T,
    4. Bokorny S,
    5. Stark WJ

    . Micro-organism-triggered release of silver nanoparticles from biodegradable oxide carriers allows preparation of self-sterilizing polymer surfaces. Small 2008; 4: 824-832.

    OpenUrlCrossRefPubMedWeb of Science
23. 23.↵
    1. Kollef MH,
    2. Afessa B,
    3. Anzueto A,
    4. Veremakis C,
    5. Kerr KM,
    6. Margolis BD, et al.

    Silver-coated endotracheal tubes and incidence of ventilator-associated pneumonia: the NASCENT randomized trial. JAMA 2008; 300: 805-813.

    OpenUrlCrossRefPubMedWeb of Science
24. 24.↵
    1. Pierrakos C,
    2. Vincent JL

    . Sepsis biomarkers: a review. Crit Care 2010; 14: R15.

    OpenUrlCrossRefPubMed
25. 25.↵
    1. Vincent JL,
    2. Teixeira L

    . Sepsis biomarkers. Value and limitations. Am J Respir Crit Care Med 2014; 190: 1081-1082.

    OpenUrlCrossRefPubMedWeb of Science
26. 26.↵
    1. Howes PD,
    2. Chandrawati R,
    3. Stevens MM.

    Bionanotechnology. Colloidal nanoparticles as advanced biological sensors. Science 2014; 346: 1247390.

    OpenUrlAbstract/FREE Full Text
27. 27.↵
    1. Wang S,
    2. Bi S,
    3. Wang Z,
    4. Xia J,
    5. Zhang F,
    6. Yang M, et al.

    A plasmonic aptasensor for ultrasensitive detection of thrombin via arrested rolling circle amplification. Chem Commun (Camb) 2015; 51: 7927-7930.

    OpenUrl
28. 28.↵
    1. De la Rica R,
    2. Stevens MM

    . Plasmonic ELISA for the ultrasensitive detection of disease biomarkers with the naked eye. Nat Nanotechnol 2012; 7: 821-824.

    OpenUrlCrossRefPubMed
29. 29.↵
    1. Chapman R,
    2. Lin Y,
    3. Burnapp M,
    4. Bentham A,
    5. Hillier D,
    6. Zabron A, et al.

    Multivalent nanoparticle networks enable point-of-care detection of human phospholipase-A2 in serum. ACS Nano 2015; 9: 2565-2573.

    OpenUrl
30. 30.↵
    1. Geissler D,
    2. Charbonnière LJ,
    3. Ziessel RF,
    4. Butlin NG,
    5. Löhmannsröben HG,
    6. Hildebrandt N

    . Quantum dot biosensors for ultrasensitive multiplexed diagnostics. Angew Chem Int Ed Engl 2010; 49: 1396-1401.

    OpenUrlCrossRefPubMed
31. 31.↵
    1. Lowe SB,
    2. Dick JA,
    3. Cohen BE,
    4. Stevens MM

    . Multiplex sensing of protease and kinase enzyme activity via orthogonal coupling of quantum dot-peptide conjugates. ACS Nano 2012; 6: 851-857.

    OpenUrlCrossRefPubMedWeb of Science
32. 32.↵
    1. Omri A,
    2. Suntres ZE,
    3. Shek PN

    . Enhanced activity of liposomal polymyxin B against Pseudomonas aeruginosa in a rat model of lung infection. Biochem Pharmacol 2002; 64: 1407-1413.

    OpenUrlCrossRefPubMedWeb of Science
33. 33.
    1. Walsh TJ,
    2. Finberg RW,
    3. Arndt C,
    4. Hiemenz J,
    5. Schwartz C,
    6. Bodensteiner D, et al.

    Liposomal amphotericin B for empirical therapy in patients with persistent fever and neutropenia. National Institute of Allergy and Infectious Diseases Mycoses Study Group. N Engl J Med 1999; 340: 764-771.

    OpenUrlCrossRefPubMedWeb of Science
34. 34.↵
    1. Drulis-Kawa Z,
    2. Dorotkiewicz-Jach A

    . Liposomes as delivery systems for antibiotics. Int J Pharm 2010; 387: 187-198.

    OpenUrlCrossRefPubMed
35. 35.↵
    1. Baier G,
    2. Cavallaro A,
    3. Vasilev K,
    4. Mailänder V,
    5. Musyanovych A,
    6. Landfester K

    . Enzyme responsive hyaluronic acid nanocapsules containing polyhexanide and their exposure to bacteria to prevent infection. Biomacromolecules 2013; 14: 1103-1112.

    OpenUrl
36. 36.↵
    1. Henry BD,
    2. Neill DR,
    3. Becker KA,
    4. Gore S,
    5. Bricio-Moreno L,
    6. Ziobro R, et al.

    Engineered liposomes sequester bacterial exotoxins and protect from severe invasive infections in mice. Nat Biotechnol 2015; 33: 81-88.

    OpenUrlCrossRefPubMed
37. 37.↵
    1. Herrmann IK,
    2. Urner M,
    3. Koehler FM,
    4. Hasler M,
    5. Roth-Z’graggen B,
    6. Grass RN, et al.

    Blood purification using functionalized core/shell nanomagnets. Small 2010; 6: 1388-1392.

    OpenUrlCrossRefPubMedWeb of Science
38. 38.↵
    1. Kang JH,
    2. Super M,
    3. Yung CW,
    4. Cooper RM,
    5. Domansky K,
    6. Graveline AR, et al.

    An extracorporeal blood-cleansing device for sepsis therapy. Nat Med 2014; 20: 1211-1216.

    OpenUrlCrossRefPubMed
39. 39.
    1. Lee HY,
    2. Bae DR,
    3. Park JC,
    4. Song H,
    5. Han WS,
    6. Jung JH

    . A selective fluoroionophore based on BODIPY-functionalized magnetic silica nanoparticles: removal of Pb2+ from human blood. Angew Chem Int Ed Engl 2009; 48: 1239-1243.

    OpenUrlPubMed
40. 40.
    1. Herrmann IK,
    2. Schlegel A,
    3. Graf R,
    4. Schumacher CM,
    5. Senn N,
    6. Hasler M, et al.

    Nanomagnet-based removal of lead and digoxin from living rats. Nanoscale 2013; 5: 8718-8723.

    OpenUrlCrossRefPubMed
41. 41.↵
    1. Lee JJ,
    2. Jeong KJ,
    3. Hashimoto M,
    4. Kwon AH,
    5. Rwei A,
    6. Shankarappa SA, et al.

    Synthetic ligand-coated magnetic nanoparticles for microfluidic bacterial separation from blood. Nano Lett 2014; 14: 1-5.

    OpenUrlCrossRefPubMed
42. 42.↵
    1. Stark WJ

    . Nanoparticles in biological systems. Angew Chem Int Ed Engl 2011; 50: 1242-1258.

    OpenUrlCrossRefPubMedWeb of Science
43. 43.↵
    1. Haley RW,
    2. Culver DH,
    3. White JW,
    4. Morgan WM,
    5. Emori TG,
    6. Munn VP, et al.

    The efficacy of infection surveillance and control programs in preventing nosocomial infections in US hospitals. Am J Epidemiol 1985; 121: 182-205.

    OpenUrlCrossRefPubMedWeb of Science
44. 44.↵
    1. Haley RW,
    2. White JW,
    3. Culver DH,
    4. Hughes JM

    . The financial incentive for hospitals to prevent nosocomial infections under the prospective payment system. An empirical determination from a nationally representative sample. JAMA 1987; 257: 1611-1614.

    OpenUrlCrossRefPubMedWeb of Science
45. 45.↵
    1. Boyce JM

    . Environmental contamination makes an important contribution to hospital infection. J Hosp Infect 2007; 65: 50-54.

    OpenUrlCrossRefPubMedWeb of Science
46. 46.↵
    1. Oie S,
    2. Suenaga S,
    3. Sawa A,
    4. Kamiya A

    . Association between isolation sites of methicillin-resistant Staphylococcus aureus (MRSA) in patients with MRSA-positive body sites and MRSA contamination in their surrounding environmental surfaces. Jpn J Infect Dis 2007; 60: 367-369.

    OpenUrlPubMed
47. 47.↵
    1. Hardy KJ,
    2. Oppenheim BA,
    3. Gossain S,
    4. Gao F,
    5. Hawkey PM

    . A study of the relationship between environmental contamination with methicillin-resistant Staphylococcus aureus (MRSA) and patients’ acquisition of MRSA. Infect Control Hosp Epidemiol 2006; 27: 127-132.

    OpenUrlCrossRefPubMedWeb of Science
48. 48.↵
    1. Pritchard RC,
    2. Raper RF

    . Doctors and handwashing: instilling Semmelweis’ message. Med J Aust 1996; 164: 389-390.

    OpenUrlPubMedWeb of Science
49. 49.↵
    1. Hsueh PR,
    2. Huang HC,
    3. Young TG,
    4. Su CY,
    5. Liu CS,
    6. Yen MY

    . Bacteria killing nanotechnology Bio-Kil effectively reduces bacterial burden in intensive care units. Eur J Clin Microbiol Infect Dis 2014; 33: 591-597.

    OpenUrl
50. 50.↵
    1. Chen YL,
    2. Yeh MY,
    3. Huang SY,
    4. Liu CM,
    5. Sun CC,
    6. Lu HF, et al.

    Feasibility study for epidemic prevention and control in a regional hospital. Mol Med Rep 2012; 5: 859-865.

    OpenUrl
51. 51.↵
    1. Yang L,
    2. Yu S,
    3. Lin H,
    4. Chang Y,
    5. Wang L,
    6. Chun C, et al.

    The effect of applying quality control circle in reducing nosocomial infections. Nosocom Infect Control J 2001; 11: 137-147.

    OpenUrl
52. 52.↵
    1. Weber DJ,
    2. Rutala WA,
    3. Miller MB,
    4. Huslage K,
    5. Sickbert-Bennett E

    . Role of hospital surfaces in the transmission of emerging health care-associated pathogens: norovirus, Clostridium difficile, and Acinetobacter species. Am J Infect Control 2010; 38: S25-S33.

    OpenUrlCrossRefPubMedWeb of Science
53. 53.↵
    1. Passaretti CL,
    2. Otter JA,
    3. Reich NG,
    4. Myers J,
    5. Shepard J,
    6. Ross T, et al.

    An evaluation of environmental decontamination with hydrogen peroxide vapor for reducing the risk of patient acquisition of multidrug-resistant organisms. Clin Infect Dis 2013; 56: 27-35.

    OpenUrlCrossRefPubMed
54. 54.↵
    1. Haley RW,
    2. Morgan WM,
    3. Culver DH,
    4. White JW,
    5. Emori TG,
    6. Mosser J, et al.

    Update from the SENIC project. Hospital infection control: recent progress and opportunities under prospective payment. Am J Infect Control 1985; 13: 97-108.

    OpenUrlCrossRefPubMedWeb of Science
55. 55.↵
    1. Tseng SH,
    2. Lee CM,
    3. Lin TY,
    4. Chang SC,
    5. Chuang YC,
    6. Yen MY, et al.

    Combating antimicrobial resistance: antimicrobial stewardship program in Taiwan. J Microbiol Immunol Infect 2012; 45: 79-89.

    OpenUrlCrossRefPubMed
56. 56.↵
    1. Hsueh PR,
    2. Teng LJ,
    3. Chen CY,
    4. Chen WH,
    5. Yu CJ,
    6. Ho SW, et al.

    Pandrug-resistant Acinetobacter baumannii causing nosocomial infections in a university hospital, Taiwan. Emerg Infect Dis 2002; 8: 827-832.

    OpenUrlCrossRefPubMedWeb of Science
57. 57.↵
    1. Ohl M,
    2. Schweizer M,
    3. Graham M,
    4. Heilmann K,
    5. Boyken L,
    6. Diekema D

    . Hospital privacy curtains are frequently and rapidly contaminated with potentially pathogenic bacteria. Am J Infect Control 2012; 40: 904-906.

    OpenUrlCrossRefPubMed
58. 58.↵
    1. Nseir S,
    2. Blazejewski C,
    3. Lubret R,
    4. Wallet F,
    5. Courcol R,
    6. Durocher A

    . Risk of acquiring multidrug-resistant Gram-negative bacilli from prior room occupants in the intensive care unit. Clin Microbiol Infect 2011; 17: 1201-1208.

    OpenUrlCrossRefPubMed
59. 59.↵
    1. Hu TY,
    2. Frieman M,
    3. Wolfram J

    . Insights from nanomedicine into chloroquine efficacy against COVID-19. Nat Nanotechnol 2020; 15: 247-249.

    OpenUrlCrossRefPubMed
60. 60.↵
    1. Imani SM,
    2. Ladouceur L,
    3. Marshall T,
    4. Maclachlan R,
    5. Soleymani L,
    6. Didar TF

    . Antimicrobial nanomaterials and coatings: current mechanisms and future perspectives to control the spread of viruses including SARS-CoV-2. ACS Nano 2020; 14: 12341-12369.

    OpenUrl
61. 61.↵
    1. Dourado E

    . Accelerating availability of vaccine candidates for COVID-19. [Updated 2020; accessed 3 Feb 2024]. Available from: https://papers.ssrn.com/sol3/papers.cfm?abstract_id=3564664
62. 62.↵
    1. Itani R,
    2. Tobaiqy M,
    3. Al Faraj A

    . Optimizing use of theranostic nanoparticles as a life-saving strategy for treating COVID-19 patients. Theranostics 2020; 10: 5932-5942.

    OpenUrl
63. 63.↵
    1. Fathizadeh H,
    2. Maroufi P,
    3. Momen-Heravi M,
    4. Dao S,
    5. Köse Ş,
    6. Ganbarov K, et al.

    Protection and disinfection policies against SARS-CoV-2 (COVID-19). Infez Med 2020; 28: 185-191.

    OpenUrlPubMed
64. 64.↵
    1. Mody VV,
    2. Siwale R,
    3. Singh A,
    4. Mody HR

    . Introduction to metallic nanoparticles. J Pharm Bioallied Sci 2010; 2: 282-289.

    OpenUrlCrossRefPubMed
65. 65.↵
    1. Shahzadi S,
    2. Zafar N,
    3. Sharif R

    . Antibacterial activity of metallic nanoparticles. [Updated 2018; accessed 5 Feb 2024]. Available from: https://www.intechopen.com/chapters/59058
66. 66.↵
    1. Sportelli MC,
    2. Izzi M,
    3. Kukushkina EA,
    4. Hossain SI,
    5. Picca RA,
    6. Ditaranto N, et al.

    Can nanotechnology and materials science help the fight against SARS-CoV-2? Nanomaterials (Basel) 2020; 10: 802.

    OpenUrl
67. 67.↵
    1. Balagna C,
    2. Perero S,
    3. Percivalle E,
    4. Nepita EV,
    5. Ferraris M

    . Virucidal effect against coronavirus SARS-CoV-2 of a silver nanocluster/silica composite sputtered coating. Open Ceramics 2020; 1: 100006.

    OpenUrl
68. 68.↵
    1. Weiss C,
    2. Carriere M,
    3. Fusco L,
    4. Capua I,
    5. Regla-Nava JA,
    6. Pasquali M, et al.

    Toward nanotechnology-enabled approaches against the COVID-19 pandemic. ACS Nano 2020; 14: 6383-6406.

    OpenUrl
69. 69.↵
    1. Widdowson N

    . New mask material can remove virus-size nanoparticles. [Updated 2020; accessed 05 Feb 2024]. Available from: https://phys.org/news/2020-04-mask-material-virus-size-nanoparticles.html
70. 70.↵
    1. Palmieri V,
    2. Papi M

    . Can graphene take part in the fight against COVID-19? Nano Today 2020; 33: 100883.

    OpenUrl
71. 71.↵
    1. Talebian S,
    2. Wallace GG,
    3. Schroeder A,
    4. Stellacci F,
    5. Conde J

    . Nanotechnology-based disinfectants and sensors for SARS-CoV-2. Nat Nanotechnol 2020; 15: 618-621.

    OpenUrl
72. 72.↵
    1. Gungordu Er S,
    2. Tabish TA,
    3. Edirisinghe M,
    4. Matharu RK

    . Antiviral properties of porous graphene, graphene oxide and graphene foam ultrafine fibers against Phi6 bacteriophage. Front Med (Lausanne) 2022; 9: 1032899.

    OpenUrl
73. 73.↵
    1. Sui X,
    2. Zhang R,
    3. Liu S,
    4. Duan T,
    5. Zhai L,
    6. Zhang M, et al.

    RSL3 drives ferroptosis through GPX4 inactivation and ROS production in colorectal cancer. Front Pharmacol 2018; 9: 1371.

    OpenUrlCrossRef
74. 74.↵
    1. Singh S,
    2. Singh A

    . Current status of nanomedicine and nanosurgery. Anesth Essays Res 2013; 7: 237-242.

    OpenUrl
75. 75.↵
    1. Chang TM

    . 50th anniversary of artificial cells: their role in biotechnology, nanomedicine, regenerative medicine, blood substitutes, bioencapsulation, cell/stem cell therapy and nanorobotics. Artif Cells Blood Substit Immobil Biotechnol 2007; 35: 545-554.

    OpenUrlPubMed
76. 76.↵
    1. Martel S,
    2. Felfoul O,
    3. Mathieu JB,
    4. Chanu A,
    5. Tamaz S,
    6. Mohammadi M, et al.

    MRI-based medical nanorobotic platform for the control of magnetic nanoparticles and flagellated bacteria for target interventions in human capillaries. Int J Rob Res 2009; 28: 1169-1182.

    OpenUrl
77. 77.↵
    1. Al Sheheri SZ,
    2. Al-Amshany ZM,
    3. Al Sulami QA,
    4. Tashkandi NY,
    5. Hussein MA,
    6. El-Shishtawy RM

    . The preparation of carbon nanofillers and their role on the performance of variable polymer nanocomposites. Des Monomers Polym 2019; 22: 8-53.

    OpenUrl
78. 78.↵
    1. Ayandele E,
    2. Sarkar B,
    3. Alexandridis P

    . Polyhedral oligomeric silsesquioxane (POSS)-containing polymer nanocomposites. Nanomaterials (Basel) 2012; 2: 445-475.

    OpenUrl
79. 79.↵
    1. Hasan A,
    2. Morshed M,
    3. Memic A,
    4. Hassan S,
    5. Webster TJ,
    6. Marei HE

    . Nanoparticles in tissue engineering: applications, challenges and prospects. Int J Nanomedicine 2018; 13: 5637-5655.

    OpenUrl
80. 80.↵
    1. Yaghini E,
    2. Seifalian AM,
    3. MacRobert AJ

    . Quantum dots and their potential biomedical applications in photosensitization for photodynamic therapy. Nanomedicine (Lond) 2009; 4: 353-363.

    OpenUrl
81. 81.↵
    1. Mahmoud W,
    2. Sukhanova A,
    3. Oleinikov V,
    4. Rakovich YP,
    5. Donegan JF,
    6. Pluot M, et al.

    Emerging applications of fluorescent nanocrystals quantum dots for micrometastases detection. Proteomics 2010; 10: 700-716.

    OpenUrlPubMed
82. 82.↵
    1. Jennings LE,
    2. Long NJ

    . ‘Two is better than one’--probes for dual-modality molecular imaging. Chem Commun (Camb) 2009: 3511-3524.
83. 83.↵
    1. Ferreira L,
    2. Karp JM,
    3. Nobre L,
    4. Langer R

    . New opportunities: the use of nanotechnologies to manipulate and track stem cells. Cell Stem Cell 2008; 3: 136-146.

    OpenUrlCrossRefPubMedWeb of Science
84. 84.↵
    1. Malam Y,
    2. Loizidou M,
    3. Seifalian AM

    . Liposomes and nanoparticles: nanosized vehicles for drug delivery in cancer. Trends Pharmacol Sci 2009; 30: 592-599.

    OpenUrlCrossRefPubMedWeb of Science
85. 85.↵
    1. De Mel A,
    2. Jell G,
    3. Stevens MM,
    4. Seifalian AM

    . Biofunctionalization of biomaterials for accelerated in situ endothelialization: a review. Biomacromolecules 2008; 9: 2969-2979.

    OpenUrlCrossRefPubMedWeb of Science
86. 86.↵
    1. Zawadzak E,
    2. Bil M,
    3. Ryszkowska J,
    4. Nazhat SN,
    5. Cho J,
    6. Bretcanu O, et al.

    Polyurethane foams electrophoretically coated with carbon nanotubes for tissue engineering scaffolds. Biomed Mater 2009; 4: 015008.

    OpenUrlPubMed
87. 87.↵
    1. Waheed S,
    2. Li Z,
    3. Zhang F,
    4. Chiarini A,
    5. Armato U,
    6. Wu J

    . Engineering nano-drug biointerface to overcome biological barriers toward precision drug delivery. J Nanobiotechnology 2022; 20: 395.

    OpenUrl
88. 88.↵
    1. Bruna T,
    2. Maldonado-Bravo F,
    3. Jara P,
    4. Caro N

    . Silver nanoparticles and their antibacterial applications. Int J Mol Sci 2021; 22: 7202.

    OpenUrl
89. 89.↵
    1. Mubeen B,
    2. Ansar AN,
    3. Rasool R,
    4. Ullah I,
    5. Imam SS,
    6. Alshehri S, et al.

    Nanotechnology as a novel approach in combating microbes providing an alternative to antibiotics. Antibiotics (Basel) 2021; 10: 1473.

    OpenUrl
90. 90.↵
    1. Wu MJ,
    2. Feng YS,
    3. Sung WP,
    4. Surampalli RY

    . Quantification and analysis of airborne bacterial characteristics in a nursing care institution. J Air Waste Manag Assoc 2011; 61: 732-739.

    OpenUrlPubMed
91. 91.↵
    1. Wong V,
    2. Staniforth K,
    3. Boswell TC

    . Environmental contamination and airborne microbial counts: a role for hydroxyl radical disinfection units? J Hosp Infect 2011; 78: 194-199.

    OpenUrlPubMed
92. 92.↵
    1. Wang JL,
    2. Chen ML,
    3. Lin YE,
    4. Chang SC,
    5. Chen YC

    . Association between contaminated faucets and colonization or infection by nonfermenting gram-negative bacteria in intensive care units in Taiwan. J Clin Microbiol 2009; 47: 3226-3230.

    OpenUrlAbstract/FREE Full Text